# Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

> **NCT04678102** · PHASE1 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** PHI-101 administration

## Key facts

- **NCT ID:** NCT04678102
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678102, "Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04678102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*